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INTRODUCTION
Cigarette smoking is an important factor associated with poor 
symptom control and treatment resistance in patients with asth-
ma.
1–3 In our previous study in Korea, 18.8% of patients with asth-
ma were current smokers.
4 Asthmatic patients who smoke have 
more emergency department admissions with exacerbations,
5 
worse symptom control,
6–8 accelerated decline in lung function,
9,10 
and increased mortality rates
11 compared to non-smokers with 
asthma. Asthmatic smokers have a greater need for rescue med-
ication,
12 poorer health-status indices,
13 reduced therapeutic re-
sponse to corticosteroids,
2,3 and enhanced airway inflamma-
tion.
14-16 Thus, a need exists to develop novel therapies to target 
this subgroup of patients with asthma.
Although previous studies on the effects of smoking on asth-
ma have improved our understanding of airway inflammation 
and therapeutic response, further research is needed to clarify 
the role of smoking in asthma. Few studies have examined the 
effects of smoking cessation on symptoms, lung function, ther-
apeutic responsiveness, and quality of life (QOL). In the present 
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study, we evaluated the effect of smoking cessation on lung func-
tion and QOL in patients with asthma during corticosteroid treat-
ment.
MATERIALS AND METHODS
Subjects and study protocol
The subjects were recruited from the Asthma Genome Research 
Center, Soonchunhyang University Bucheon Hospital, Korea. A 
clinical history was obtained for each patient on the first day of 
the study using a physician-administered questionnaire. Chest 
posterior–anterior and Water’s view radiography, allergy skin 
prick tests, and spirometry (including bronchodilator respons-
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Purpose:  Smoking elicits airway inflammation and airflow obstruction in patients with asthma, even after smoking cessation. The aim of this study 
was to examine the effects of smoking cessation on lung function and quality of life (QOL) in asthmatic patients. Methods:  Thirty-two patients with 
asthma who were active smokers were recruited. After education on the effects of smoking on asthma, 22 patients continued to smoke, and 10 quit 
smoking. All patients were treated with inhaled fluticasone propionate (1 mg/day) for 3 months. We compared forced expiratory volume in 1 s (FEV1), 
FEV1/forced vital capacity (FVC), forced expiratory flow between 25 and 75% FVC (FEF25–75%), and scores on a QOL questionnaire at baseline, 1, 2, 
and 3 months. Results:  Quitters showed a greater percent change in FEV1 (19.1±6.3 vs. 7.9±2.4%, P=0.024) and FEV1/FVC (6.5±4.14 vs. 3.5±
1.5%, P=0.05) than smokers. Both quitters and smokers showed improved QOL scores after 1, 2, and 3 months of fluticasone treatment. Conclu-
sions:  Patients with asthma who quit smoking showed less airway obstruction, suggesting that smoking cessation is crucial in the management of 
asthma.
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es after the inhalation of two puffs of 100 μg aerosolized albuter-
ol) were performed. On the second visit, airway hyperrespon-
siveness (AHR) was measured in cases with predicted values 
for forced expiratory volume in 1 s (FEV1) ≥70%. All patients 
showed airway reversibility, as indicated by inhalant broncho-
dilator-induced improvement of >15% in FEV1 and/or airway 
hyperreactivity under <10 mg/mL methacholine.
17 All asthmat-
ics smoked during the first and second visit. Asthmatics (n=35) 
with moderate persistent severity had compatible clinical symp-
toms and physical characteristics according to the Global Ini-
tiative for Asthma guidelines.
18 All subjects provided informed 
consent, and the protocols were approved by the local ethics 
committees. The patients were educated visually in the use of 
inhaled glucocorticoid (GC) by a trained nurse until their accu-
racy scores reached 12 (out of a maximum score of 14). GC in-
halation was maintained for 3 months. Inhaled GC was 1 mg/
day fluticasone propionate, which was self-administered using 
a multi-dose dry-powder inhaler (two puffs b.i.d.; Diskhaler, GSK, 
Durham, NC, USA). The patients used short-acting bronchodi-
lators as needed. We educated all patients with asthma regard-
ing the effects of smoking on health. Patients were classified into 
quitters and continuing smokers. FEV1, FEV1/forced vital ca-
pacity (FVC), forced expiratory flow between 25 and 75% FVC 
(FEF25–75%), and score on the asthma-related QOL questionnaire 
(AQLQ) at baseline and at 1, 2, and 3 months were compared be-
tween groups.
Lung function tests
Baseline FVC and FEV1 measurements were obtained in the 
absence of recent bronchodilator use (within 8 h) and selected 
according to the American Thoracic Society criteria.
19 Basal and 
post-bronchodilator FEV1, FVC, and FEF25–75% were measured. 
AHR was measured via methacholine challenge and was ex-
pressed as the provocation concentration that caused a fall in 
FEV1 of 20% (PC20) in non-cumulative units.
20
IgE measurement and skin allergy tests
Total IgE was measured using the UniCAP system (Pharmacia 
Diagnostics, Uppsala, Sweden). Allergy skin prick tests were per-
formed using commercially available inhalant allergens (Ben-
card, Devon, UK), which included dust mites (Dermatophagoi-
des farinae and D. pteronyssinus) and histamine (1 mg/mL). No 
subject had received oral antihistamines in the 3 days preced-
ing the study. All tests included positive (1 mg/mL histamine) 
and negative (diluent) controls. After 15 minutes, the mean di-
ameter of the wheals formed by each allergen was compared 
with that formed by histamine. If the former was the same or 
larger than the latter (A/H ratio ≥1.0) or the mean diameter was 
>3 mm, the reaction was deemed positive. Atopy was deter-
mined by the presence of an immediate skin reaction to one or 
more aeroallergens, as described previously.
21
QOL measurement
The AQLQ was evaluated at baseline and after 4 weeks of treat-
ment, using a Korean translation of the Juniper AQLQ.
22 The an-
swers to each question were scored on a five-point scale, with a 
score of 1 representing the greatest impairment, and a score of 
5 representing no impairment (lower AQLQ scores reflected in-
creased impairment). Items were weighted equally and report-
ed as the mean score for each domain (activity limitation, emo-
tions, symptoms, and exposure to environmental stimuli), along 
with the overall score.
Statistical analysis
Group differences were compared using two-sample t-tests, 
Wilcoxon rank-sum tests, and the Pearson χ
2 test for normally 
distributed, skewed, and categorical data, respectively. Data are 
expressed as the mean and standard error of the mean. A P-value 
of less than 0.05 was considered statistically significant.
RESULTS
Thirty-five asthmatic patients who were active smokers were 
recruited for this prospective study (Fig. 1). Three patients with-
drew; two patients had restarted smoking, and one patient was 
not able to complete the QOL. Thus, 32 patients with asthma 
were enrolled. After education about the effects of smoking on 
overall health and on asthma in particular, 22 patients continued 
to smoke, and 10 quit smoking. Descriptive statistics according 
to smoking status in patients with asthma are shown in Table. 
Current smokers had a higher number of pack-years compared 
with patients who quit smoking (23.5±13.6 versus 6.5±2.2, re-
spectively; P=0.001). The level of IgE and atopy prevalence tend-
ed to be higher among current smokers than among quitters.
Both quitters and smokers showed an increase in predicted 
FEV1 following steroid treatment (baseline versus 1, 2, and 3 
months: quitters, 73.6±5.6 versus 91.1±5.2, 92.5±4.3, and 101.1± 
10.1%; smokers, 68.2±2.4 versus 76.9±3.7, 75.5±4.1, and 78.4± 
5.9%; Fig. 2A). FEV1/FVC (baseline versus 1, 2, and 3 months: 
quitters, 68.8±3.3 versus 75.5±2.7, 77.0±4.4, and 87.6±6.3%; 
smokers, 67.1±1.9 versus 70.5±2.3, 68.5±2.5, and 69.5±3.9%; Fig. 
2B) tended to be higher in quitters than in smokers. FEF25–75% 
was higher in quitters than in smokers (baseline versus 1, 2, and 
3 months: quitters, 49.2±6.1 versus 70.8±7.5, 77.0±4.4, and 100.6± 
Fig. 1.  Study design.
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18.4%; smokers, 44.5±4.0 versus 60.8±5.9, 56.7±6.1, and 59.5± 
8.0%; Fig. 2C). Quitters showed a significantly greater increase 
in percent change in FEV1 and FEV1/FVC than did current 
smokers at 1 month (FEV1: 19.1±6.3 versus 7.9±2.4%, P=0.024; 
FEV1/FVC: 6.5±4.14 versus 3.5±1.5%, P=0.05; Fig. 3). Both quit-
ters and smokers showed improved AQLQ scores (baseline ver-
sus 1, 2, and 3 months: quitters, 52.1±2.5 versus 62.5±3.1, 68.7± 
3.5, and 76.8±2.4; smokers, 53.2±1.7 versus 64.3±1.6, 68.9±2.5, 
and 67.7±3.3; Fig. 4). The percent change in QOL did not differ 
between quitters and smokers.
DISCUSSION
In this study, smoking cessation in patients with asthma im-
proved lung function, indicating that smoking cessation is a very 
important factor in asthma management.
Both morbidity and mortality due to asthma increase in indi-
viduals who smoke compared with those who have never 
smoked.
1–4 Asthmatic smokers show more severe asthmatic 
symptoms,
6 a greater need for rescue medication,
12 and poorer 
health-status indices than never-smokers.
12,13 Smoking a ciga-
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Table.  Baseline clinical profiles of the subjects
  Quit group Smoking group
No. of patients 10 22
Gender (male/female) 7/3 20/2
Age (yr) 53.3±4.3 45.6±2.5
FEV1, % predicted 73.6±5.6 68.2±2.4
FVC, % predicted 77.8±3.7 77.2±1.9
FEV1/FVC 68.8±3.3 67.1±1.9
FEF25-75% 49.2±6.1 44.5±4.0
Atopy (%) 33.3 (2/6) 75 (12/16)
Duration of asthma (yr) 16.6±10.3 10.2±2.2
Pack years smoked 6.5±2.2 23.5±13.6*
PC20 methacholine 5.3±7.9 5.4±6.4
Total IgE (Unit) 463.3±156.2 600.3±228.2
Plus–minus values are mean±SE.
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEF25–75%, 
forced expiratory flow between 25 and 75% FVC; PC20 methacholine, the con-
centration of methacholine required to decrease the FEV1 by 20%.
*P=0.001 compared with quit group.
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steroid treatment in quitters and smokers. C
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rette can cause acute bronchoconstriction, although tobacco 
smoke does not act as an acute irritant in all patients.
23 Baseline 
FEV1 is directly related to the immediate response to inhaling 
cigarette smoke,
24 suggesting that asthmatic smokers with rela-
tively poor lung function are particularly susceptible to the acute 
effects of tobacco smoke. Emergency department visits as a re-
sult of exacerbated asthma occur more frequently among heavy 
cigarette smokers after days with high levels of ambient ozone 
pollution,
25 and hospital admission rates for asthma and hospi-
tal-based care are higher in smokers.
13,18,26 There is conflicting 
evidence as to whether current smoking is a risk factor for near-
fatal or fatal asthma.
27,28 In a previous prospective controlled study, 
subjects who quit smoking achieved considerable improvement 
in lung function and decreased sputum neutrophil count with-
in 3 months compared with subjects who continued to smoke.
29 
In our study, patients with asthma who were current smokers 
tended to have lower baseline FEV1 values than did quitters, sug-
gesting that continued smoking results in a greater decrease in 
lung function in long-term asthmatic smokers. The differences 
between our results and those of Chaudhuri et al.
29 seem to be 
due to patient selection and study duration.
Combined cigarette smoking and asthma accelerate the decline 
in lung function to a greater degree than either factor alone.
9,10,30 
In a previous study, the synergistic effect of combined asthma 
and smoking resulted in a 17.8% decline in FEV1 over 10 years.
9 
In contrast, smoking cessation improved symptoms and bron-
chial hyper-responsiveness and decreased airway inflamma-
tion.
3 In our study, asthmatic smokers had a higher number of 
pack-years (23.5±13.6) than asthmatics who had quit (6.5±2.2, 
P=0.001), indicating that a long-term addiction is more difficult 
to break. Therefore, long-term smokers are likely to require more 
anti-smoking education.
International guidelines for asthma management recommend 
inhaled corticosteroids as the most effective anti-inflammatory 
therapy for chronic asthma.
18 The evidence for this recommen-
dation is based on clinical studies that have been undertaken 
largely in patients with asthma who have never smoked or who 
were former smokers. Asthmatic smokers, however, may be re-
sistant to the beneficial therapeutic effects of corticosteroids due 
to several clinical factors.
2,3 The mechanism underlying cortico-
steroid resistance in asthmatic smokers is largely unstudied, but 
may include one or more of the pathways implicated in asth-
matic non-smokers and other inflammatory diseases. Alterna-
tive or additional treatment to inhaled corticosteroids may be 
required for asthmatics who are unable to stop smoking or who 
have persistent symptoms after quitting.
14 In our study, patients 
who quit smoking showed greater improvement in lung func-
tion than current smokers, indicating that quitting is an impor-
tant factor in asthma treatment. Among atopic patients with 
asthma, smokers are less responsive to inhaled adenosine than 
non-smokers, which reflects differences in airway inflamma-
tion.
31 Cigarette smoking may modulate inflammation associat-
ed with asthma. In previous studies, cigarette smoking induced 
airway inflammation in non-asthmatic smokers without airflow 
obstruction compared to non-smokers.
32,33 Normal smokers 
show increased T-lymphocyte cell counts, particularly CD8 
cells,
32 and macrophage cell counts within airway walls, higher 
neutrophil numbers within bronchial secretions, and infiltra-
tion of peripheral airways by mononuclear cells and macro-
phages.
16,32,33. In our study, we did not identify the effects of smok-
ing on airway inflammation. Further studies are needed to clar-
ify the effects of smoking on airway inflammation using sputum 
cells in a larger population of patients with asthma.
Recent studies of outcomes in patients with asthma have fo-
cused on clinical and physiological measures.
34 Because such 
clinical measures do not provide a complete, accurate view of 
the impact of a disease on an individual’s physical, social, or emo-
tional well being, health-related QOL measures are increasingly 
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being integrated into clinical research on asthma.
22,34,35 AQLQ 
scores have been used as a tool to measure the outcome of drug 
treatment. AQLQ scores may reveal benefits of asthma treatment 
not apparent via objective monitoring and complement clinical 
and physiological assessments of treatment outcome.
36 In the 
present study, we found that overall AQLQ scores improved in 
quitters and continuing smokers after treatment with inhaled 
GCs, indicating that corticosteroids may be valuable in the con-
trol of asthma regardless of smoking status. The limitations of 
this study were that the number of subjects was small and that 
the smoking group had more pack years; therefore, we could not 
exclude a long-standing smoking effect on pulmonary function.
In conclusion, patients with asthma who quit smoking showed 
greater improvement in airway obstruction than patients who 
continued smoking, suggesting that smoking cessation is of ther-
apeutic benefit in the management of asthma.
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